Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1990 1
2006 1
2007 2
2008 4
2009 3
2010 3
2011 2
2012 3
2013 6
2014 1
2015 1
2016 5
2017 5
2018 5
2019 12
2020 11
2021 10
2022 15
2023 15
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, Tonea R, Ovcinnikovs V, Lloyd K, Schuurman J, Riesenfeld SJ, Gajewski TF, de Miranda NFCC, van Hall T, van der Burg SH. van Elsas MJ, et al. Among authors: de miranda nfcc. Cancer Cell. 2024 Jun 10;42(6):1032-1050.e10. doi: 10.1016/j.ccell.2024.04.011. Epub 2024 May 16. Cancer Cell. 2024. PMID: 38759656 Free article.
An integrated tumor, immune and microbiome atlas of colon cancer.
Roelands J, Kuppen PJK, Ahmed EI, Mall R, Masoodi T, Singh P, Monaco G, Raynaud C, de Miranda NFCC, Ferraro L, Carneiro-Lobo TC, Syed N, Rawat A, Awad A, Decock J, Mifsud W, Miller LD, Sherif S, Mohamed MG, Rinchai D, Van den Eynde M, Sayaman RW, Ziv E, Bertucci F, Petkar MA, Lorenz S, Mathew LS, Wang K, Murugesan S, Chaussabel D, Vahrmeijer AL, Wang E, Ceccarelli A, Fakhro KA, Zoppoli G, Ballestrero A, Tollenaar RAEM, Marincola FM, Galon J, Khodor SA, Ceccarelli M, Hendrickx W, Bedognetti D. Roelands J, et al. Among authors: de miranda nfcc. Nat Med. 2023 May;29(5):1273-1286. doi: 10.1038/s41591-023-02324-5. Epub 2023 May 19. Nat Med. 2023. PMID: 37202560 Free PMC article.
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
de Vries NL, van de Haar J, Veninga V, Chalabi M, Ijsselsteijn ME, van der Ploeg M, van den Bulk J, Ruano D, van den Berg JG, Haanen JB, Zeverijn LJ, Geurts BS, de Wit GF, Battaglia TW, Gelderblom H, Verheul HMW, Schumacher TN, Wessels LFA, Koning F, de Miranda NFCC, Voest EE. de Vries NL, et al. Among authors: de miranda nfcc. Nature. 2023 Jan;613(7945):743-750. doi: 10.1038/s41586-022-05593-1. Epub 2023 Jan 11. Nature. 2023. PMID: 36631610 Free PMC article.
Functional and spatial proteomics profiling reveals intra- and intercellular signaling crosstalk in colorectal cancer.
Plattner C, Lamberti G, Blattmann P, Kirchmair A, Rieder D, Loncova Z, Sturm G, Scheidl S, Ijsselsteijn M, Fotakis G, Noureen A, Lisandrelli R, Böck N, Nemati N, Krogsdam A, Daum S, Finotello F, Somarakis A, Schäfer A, Wilflingseder D, Gonzalez Acera M, Öfner D, Huber LA, Clevers H, Becker C, Farin HF, Greten FR, Aebersold R, de Miranda NFCC, Trajanoski Z. Plattner C, et al. Among authors: de miranda nfcc. iScience. 2023 Nov 4;26(12):108399. doi: 10.1016/j.isci.2023.108399. eCollection 2023 Dec 15. iScience. 2023. PMID: 38047086 Free PMC article.
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, González-Prieto R, Verlaan-de Vries M, Rip J, Arens R, de Miranda NFCC, Hawinkels LJAC, van Hall T, Vertegaal ACO. Kumar S, et al. Among authors: de miranda nfcc. Gut. 2022 Nov;71(11):2266-2283. doi: 10.1136/gutjnl-2021-324834. Epub 2022 Jan 24. Gut. 2022. PMID: 35074907 Free PMC article.
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, Balduzzi S, Grootscholten C, IJsselsteijn ME, Veenhof AAFA, Hartemink KJ, Vollebergh MA, Jurdi A, Sharma S, Spickard E, Owers EC, Bartels-Rutten A, den Hartog P, de Miranda NFCC, van Leerdam ME, Haanen JBAG, Schumacher TN, Voest EE, Chalabi M. Verschoor YL, et al. Among authors: de miranda nfcc. Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8. Nat Med. 2024. PMID: 38191613 Free PMC article. Clinical Trial.
Advancing cancer immunotherapy: a vision for the field.
de Miranda NFCC, Trajanoski Z. de Miranda NFCC, et al. Genome Med. 2019 Jul 29;11(1):51. doi: 10.1186/s13073-019-0662-6. Genome Med. 2019. PMID: 31358048 Free PMC article. No abstract available.
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.
Lei X, de Groot DC, Welters MJP, de Wit T, Schrama E, van Eenennaam H, Santegoets SJ, Oosenbrug T, van der Veen A, Vos JL, Zuur CL, de Miranda NFCC, Jacobs H, van der Burg SH, Borst J, Xiao Y. Lei X, et al. Among authors: de miranda nfcc. Cell Mol Immunol. 2024 Apr;21(4):374-392. doi: 10.1038/s41423-024-01133-1. Epub 2024 Feb 21. Cell Mol Immunol. 2024. PMID: 38383773 Free PMC article.
116 results